Avantor (AVTR) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
10x Genomics (TXG) has outperformed Avantor (AVTR) over the past year, gaining 556.0% versus a gain of 14.0%. Over five years, TXG leads with a -50.0% price change compared with -60.0% for AVTR. Avantor is the larger company by market cap ($10.38 billion vs $9.92 billion), about 1.0 times the size, while 10x Genomics is growing revenue faster (+5.2% vs -3.4%).
On valuation, Avantor trades at a lower forward P/E (17.5x vs 992.6x for 10x Genomics). 10x Genomics converts more of its revenue into profit, with a net margin of -6.8% versus -8.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | TXG |
|---|---|---|
| Share price | $15.35 | $76.10 |
| Market cap | $10.38B | $9.92B |
| 1-day change | -0.52% | -5.65% |
| YTD return | +33.94% | +366.58% |
| 1-year return | +13.96% | +556.03% |
| 5-year return | -59.97% | -50.02% |
| Forward P/E | 17.48 | 992.57 |
| EPS (TTM) | $-0.84 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.55B | $642.82M |
| Revenue growth (YoY) | -3.41% | +5.25% |
| Net income (latest FY) | $-530.20M | $-43.54M |
| Gross margin | 32.65% | 69.05% |
| Operating margin | -3.76% | -9.49% |
| Net margin | -8.09% | -6.77% |
| 52-week high | $16.38 | $102.81 |
| 52-week low | $7.27 | $11.16 |
| Distance from 52-week high | -6.26% | -25.98% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -3.71% | -13.27% |
| Average volume | 9.45M | 3.15M |
| Shares outstanding | 676.36M | 120.21M |
| Employees | 13,500 | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXG has outperformed AVTR by 542.1 percentage points over the past year.
- 10x Genomics grew revenue faster in its latest fiscal year (+5.25% vs -3.41%).
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
AVTR vs TXG FAQ
Which is bigger, Avantor or 10x Genomics?
Avantor (AVTR) is larger, with a market capitalization of $10.38B compared with $9.92B for 10x Genomics (TXG).
Which stock has performed better over the past year, AVTR or TXG?
TXG returned +556.03% over the past 12 months, compared with +13.96% for AVTR (price return, excluding dividends). Past performance does not predict future results.
Are Avantor and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.